VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
41 hedge funds and large institutions have $9.95M invested in Viracta Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
64% less capital invested
Capital invested by funds: $28M → $9.95M (-$18M)
Holders
41
Holding in Top 10
2
Calls
$45K
Puts
$14K
Top Buyers
| 1 | +$64.2K | |
| 2 | +$36K | |
| 3 | +$21.5K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$21K |
| 5 |
JPMorgan Chase & Co
New York
|
+$9K |
Top Sellers
| 1 | -$3.38M | |
| 2 | -$2.46M | |
| 3 | -$1.79M | |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$1.25M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.17M |